Nephraegis Therapeutics

Nephraegis Therapeutics is a biopharmaceutical company dedicated to developing a range of promising patented drug candidates for the prevention and treatment of acute kidney injury (AKI). Their lead compound, NPH-022, is an epoxyeicosatrienoic acid-related compound (EET) with optimal pharmacokinetic properties.